Bank of Hawaii’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bank of Hawaii’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,264	Closed	-$428K	–	259
2022 Q4	$428K	Buy	+11,264	New	+$388K	0.03%	189

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of Hawaii's RETA Position: Q1 2023 in Review

Bank of Hawaii sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 11,264 shares — an estimated $428K sold.

Bank of Hawaii first reported a position in RETA in Q4 2022 and held it in 1 quarter. The position peaked at $428K in Q4 2022. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Bank of Hawaii reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Bank of Hawaii sold 11,264 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $428K.
Bank of Hawaii first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 1 quarter.
Bank of Hawaii's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $428K in Q4 2022.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Bank of Hawaii's 13F filing for Q1 2023, filed 10 May 2023.